NEWS

Coompany
thumb
2018 / 07 / 31

Pathogenic Germline Variants in 10,389 Adult Cancers

<Abstract> We conducted the largest investigation of predisposition variants in cancer to date, discovering 853 pathogenic or likely pathogenic variants in 8% of 10,389 cases from 33 cancer types. Twenty-one genes showed single or cro...

thumb
2018 / 05 / 15

Third generation EGFR TKIs: current data and future directions

<check Femtopath C797 mutation kit>   <Abstract> Acquired T790M mutation is the commonest cause of resistance for advanced non-small cell lung cancer (NSCLC) epidermal growth factor receptor (EGFR) mutant patients who had p...

thumb
2018 / 03 / 26

Pre-PCR processing of FFPE samples leads to discrepancies in BRAF and EGFR mutation detection

<Title> Variation in pre-PCR processing of FFPE samples leads to discrepancies in BRAF and EGFR mutation detection: a diagnostic RING trial <Abstract> Mutation detection accuracy has been described extensively; however, it is su...

thumb
2017 / 09 / 03

大腸瘜肉基因檢測評估說明

目前大腸癌檢測最普遍的還是用內視鏡的方式進行大腸息肉檢測,為了彌補現有病理學上面的缺口(包含:一些難辨識組織型態以及靈敏度不佳蛋白質標記),針對高風險的族群(包含有家族病史/多個或是較大息肉/年長者/或有相關慢性及疾病等等)提供息肉基因檢測服務。FemtoPath mutation screen kits 利用sanger sequencing的方式,針對檢體中基因序列直接判讀,直接看到突變點位以及突變型態,此外也可針對hot spot的位置,偵測已知以及未知的突變位點(Pa...

thumb
2017 / 07 / 24

Immunohistochemical staining for p16 and BRAFV600E is useful to distinguish between sporadic and hereditary (Lynch syndrome-related) microsatellite instable colorectal carcinomas.

<Title> Immunohistochemical staining for p16 and BRAFV600E is useful to distinguish between sporadic and hereditary (Lynch syndrome-related) microsatellite instable colorectal carcinomas. <Abstract> DNA mismatch repair (MMR) pro...

thumb
2017 / 05 / 15

ACG Clinical Guideline: Genetic Testing and Management of Hereditary Gastrointestinal Cancer Syndromes

<Abstract> This guideline presents recommendations for the management of patients with hereditary gastrointestinal cancer syndromes. The initial assessment is the collection of a family history of cancers and premalignant gastrointest...

thumb
2017 / 05 / 15

British Society of Gastroenterology position statement on serrated polyps in the colon and rectum

<Abstract> Serrated polyps have been recognised in the last decade as important premalignant lesions accounting for between 15% and 30% of colorectal cancers. There is therefore a clinical need for guidance on how to manage these lesi...

thumb
2017 / 05 / 04

A tailored approach to BRAF and MLH1 methylation testing in a universal screening program for Lynch syndrome

<Title> A tailored approach to BRAF and MLH1 methylation testing in a universal screening program for Lynch syndrome   <Abstract> To determine the correlation between BRAF genotype and MLH1 promoter methylation in a screeni...

thumb
2016 / 10 / 29

Secondary Prevention of Cervical Cancer: ASCO Resource-Stratified Clinical Practice Guideline

<Primary Screening> Human papillomavirus (HPV) DNA testing is recommended in all resource settings. Visual inspection with acetic acid may be used in basic settings. The recommended age ranges and frequencies in each setting are as fo...

thumb
2016 / 02 / 17

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy

<title> Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline <abstract> Purpose To provide recomme...

thumb
2016 / 02 / 17

Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer

<title> Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer <abstract> Purpose BRAF V600 Emutationisseenin 5% to 8% of patients with metastatic colorectal cancer (CRC) and is associated...

thumb
2015 / 10 / 14

ASCO臨床腫瘤年會發表臨床試驗論文對大腸癌標靶治療 再次要求All-Ras的檢驗應該要陰性

<Title> Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor ReceptorMonoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion ...

thumb
2015 / 07 / 29

Femtopath from Sanger to NGS Sanger to NGS-Investors

Femtopath from Sanger to NGSFemtopath from Sanger to NGSFemtopath from Sanger to NGS Femtopath from Sanger to NGSFemtopath from Sanger to NGS Femtopath from Sanger to NGS Femtopath from Sanger to NGSFemtopath from Sanger to NGS

thumb
2015 / 07 / 29

Femtopath from Sanger to NGS-Guide line

Femtopath from Sanger to NGS  Femtopath from Sanger to NGS  Femtopath from Sanger to NGS  Femtopath from Sanger to NGS  Femtopath from Sanger to NGS  Femtopath from Sanger to NGS  Femtopath from Sanger to NGS  Femtopath from Sanger to NGS  ...

loading